HTA decisions are the scientific gatekeeper for market access, providing the payer-negotiated insights necessary for pricing, coverage, and commercial success.
These reviews are resource-intensive. When fragmented or delayed, companies can lose crucial market access windows and the ability to proactively influence future appraisals.
Biolevate bridges this gap by enabling teams to scale HTA reviews without compromising accuracy, ensuring a full and defensible rationale at every step.
16× faster HTA reviews
Reduce cycle time from ~80+ to ~5 days per HTA review by automating decision retrieval, screening, extraction, and first-draft rationales.
9× broader coverage
Scale from ~180 to 2,000+ decisions reviewed per year (vs typical insourcing volumes) by applying expert logic across the full corpus.
99% accuracy, consistent outputs
Standardized logics and source-linked extraction improve consistency across teams, with accuracy up to ~99% (vs ~95% human-only baselines).
How it works
1
Retrieve and filter past HTA decisions — pull decisions from internal repositories and public sources (e.g., NICE, G-BA, HAS, CADTH) to build a complete, searchable corpus.
2
Define a screening rationale — select a critical subset (same indication/comparator/endpoints/setting) and let Biolevate scale the criteria across the corpus to produce a curated, review-ready set.
3
Extract arguments and evidence patterns — capture key decision drivers (comparators, endpoints, uncertainty, subgroups, cost-effectiveness, RWE expectations) into structured tables with traceable sources.
4
Generate dossier-ready rationales — produce the first version of your argumentation and evidence story using your templates, grounded in extracted data and linked to decision sources for validation.
Reusable decision base: a structured, searchable library of HTA decisions and rationales reusable across indications and markets.
Defensible outputs: source-linked claims with a run record to support internal review and payer-facing credibility.